The HTT CAG-Expansion Mutation Determines Age at Death but Not Disease Duration in Huntington Disease

• Published in: American journal of human genetics Vol. 98; no. 2; pp. 287 - 298
• Main Authors: Keum, Jae Whan, Shin, Aram, Gillis, Tammy, Mysore, Jayalakshmi Srinidhi, Abu Elneel, Kawther, Lucente, Diane, Hadzi, Tiffany, Holmans, Peter, Jones, Lesley, Orth, Michael, Kwak, Seung, MacDonald, Marcy E., Gusella, James F., Lee, Jong-Min
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 04.02.2016; Cell Press; Elsevier
• Subjects: Adolescent; Adult; Age; Age Factors; Aged; Aged, 80 and over; Alleles; Child; Child, Preschool; Cohort Studies; Corpus Striatum - metabolism; Genetics; Haplotypes; Humans; Huntingtin Protein; Huntington Disease - genetics; Huntington Disease - mortality; Huntingtons disease; Middle Aged; Mortality; Mutation; Nerve Tissue Proteins - genetics; Nerve Tissue Proteins - metabolism; Young Adult
• ISSN: 0002-9297; 1537-6605; 1537-6605
• DOI: 10.1016/j.ajhg.2015.12.018

Huntington disease (HD) is caused by an expanded HTT CAG repeat that leads in a length-dependent, completely dominant manner to onset of a characteristic movement disorder. HD also displays early mortality, so we tested whether the expanded CAG repeat exerts a dominant influence on age at death and on the duration of clinical disease. We found that, as with clinical onset, HD age at death is determined by expanded CAG-repeat length and has no contribution from the normal CAG allele. Surprisingly, disease duration is independent of the mutation’s length. It is also unaffected by a strong genetic modifier of HD motor onset. These findings suggest two parsimonious alternatives. (1) HD pathogenesis is driven by mutant huntingtin, but before or near motor onset, sufficient CAG-driven damage occurs to permit CAG-independent processes and then lead to eventual death. In this scenario, some pathological changes and their clinical correlates could still worsen in a CAG-driven manner after disease onset, but these CAG-related progressive changes do not themselves determine duration. Alternatively, (2) HD pathogenesis is driven by mutant huntingtin acting in a CAG-dependent manner with different time courses in multiple cell types, and the cellular targets that lead to motor onset and death are different and independent. In this scenario, processes driven by HTT CAG length lead directly to death but not via the striatal pathology associated with motor manifestations. Each scenario has important ramifications for the design and testing of potential therapeutics, especially those aimed at preventing or delaying characteristic motor manifestations.